Replies to post #32476 on Biotech Values

[DewDiligence]

> ANDS – "They don't expect to resume studies for ANA975 for SEVERAL QUARTERS?"<

I did not consider that revelation surprising because it takes a while to resolve a clinical hold based on a problem in animal tox. COR is a case in point.

I thought a more significant revelation from the ANDS CC was that NVS did not opt to license ANA380 during the period of contractual exclusivity.